ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / IVA / insiders
ALMS (19) OBX (34) CRVS (27) JBIO (31) ⌘ Pro Terminal →

Inventiva S.A. American Depository Shares (IVA) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$3.65 -2.14% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.63

Inventiva S.A. American Depository Shares (IVA) carries a Roarable Rating of D (Sell) with 49/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (49/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →
ROARABLE D • SELL / AVOID Cap $881.3M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on IVA Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is IVA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-02, Inventiva S.A. American Depository Shares (NASDAQ: IVA) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 49/100 at a spot price of $3.65 (-2.14% 1D, market cap $881.3M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, IVA ranks #310 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does IVA compare to ALMS and OBX in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), IVA carries a Roarable D (49/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, ALMS (Alumis Inc.) holds a E grade (19/100 RQD, P/E N/A, ROIC -35.0%, cap $891.8M) and OBX (Obsidian Therapeutics Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $896.9M). Among the 5-stock peer group, IVA leads on earnings multiple (N/A) while ALMS leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for IVA?
▼

For Inventiva S.A. American Depository Shares (IVA), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #310 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $3.63 (-0.58%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0.6% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (49/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.4% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510049
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk D+
Cash (12)Whales (7)SEC (13)Macro (8)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-4.1% Base Target
$8 Bull$4 Base$3 Bear
📬 FREE IVA RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for IVA)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (49/100 Composite)
🔍 WHY IVA SCORES 49/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (27% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (24% of score)

SEC XBRL Trailing 12 Months: 0.6% FCF Margin ($24.7M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning7/20 pts (-13 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-13 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
41
Grade D$3.12-4.5% Next Q
Q2 (-2Q)
44
Grade D$2.98+22.8% Next Q
Q3 (-1Q)
46
Grade D$3.66-0.3% Next Q
Current
49
Grade D$3.65-5.4% Hist 90D α
Trajectory: D (41) → D (49)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a IVA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While IVA currently carries a cautious 49/100 (D) rating due to Whale & Options Positioning (7/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.80) and Max Pain ($3.83) forces dealer call-delta covering toward $7.65.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $IVA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “IVA Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
YES 49%NO 51%Trade / Inspect Odds →
SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

IVA Smart-Money Thermometer: BALANCED INSTITUTIONAL POSITIONING

Explore All 13F & Congress Whales →
▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (IVA)

No recent open-market Form 4 cluster sales or emergency dumps flagged on IVA. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring IVA)

  • ✓Walkthrough of IVA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
IVA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -30.74%📐 HORIZONTAL RANGE
2026-11-02O $3.71H $3.73L $3.65C $3.65VOL 1.44M
RES: $5.46SUP: $2.28SMA50: $3.80SMA200: $4.87
$6.29$5.35$4.41$3.47$2.53RES $5.46SUP $2.28$3.652026-05-042026-06-172026-08-042026-09-172026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

IVA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 IVA Butterfly Map → + Track IVA →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on IVA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for IVA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for IVA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (IVA)

Health Care Rank #310 of 1016 ⚔️ ALMS vs IVA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (IVA vs. ALMS, OBX, CRVS, JBIO)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Inventiva S.A. American Depository Shares (IVA) ranks #310 by composite RQD confidence (49/100, grade D) and #379 by equity capitalization ($881.3M). Within this direct 5-issuer industry benchmark cohort, IVA leads on earnings valuation at N/A trailing P/E, while ALMS leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. IVA currently leads its immediate peer cohort in composite quantitative strength at 49/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
IVA ACTIVE
Inventiva S.A. American Depository Shares
D 49/100 — — — -2.14% $881.3M Benchmark Subject
ALMS
Alumis Inc.
E 19/100 — — -35.0% -2.32% $891.8M /alms-vs-iva →
OBX
Obsidian Therapeutics Inc.
E 34/100 — — -35.0% +1.86% $896.9M /obx-vs-iva →
CRVS
Corvus Pharmaceuticals Inc.
E 27/100 — — -35.0% -1.95% $860.6M /crvs-vs-iva →
JBIO
Jade Biosciences Inc.
E 31/100 — — -35.0% -1.26% $905.6M /jbio-vs-iva →

2. IVA Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Inventiva S.A. American Depository Shares (IVA) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $881.3M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. IVA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is IVA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, Inventiva S.A. American Depository Shares (NASDAQ: IVA) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 49/100 at a spot price of $3.65 (-2.14% 1D, market cap $881.3M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, IVA ranks #310 in composite RQD confidence.

How does IVA compare to ALMS and OBX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), IVA carries a Roarable D (49/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, ALMS (Alumis Inc.) holds a E grade (19/100 RQD, P/E N/A, ROIC -35.0%, cap $891.8M) and OBX (Obsidian Therapeutics Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $896.9M). Among the 5-stock peer group, IVA leads on earnings multiple (N/A) while ALMS leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for IVA?

For Inventiva S.A. American Depository Shares (IVA), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #310 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is IVA trading relative to its 50-day, 200-day, and 52-week technical levels?

IVA last traded at $3.65 (-2.14% on volume of 1,730,076 shares), positioning the stock -3.95% below its 50-day simple moving average ($3.80) and -25.05% below its 200-day simple moving average ($4.87). Across its 52-week range of $2.82 to $7.29, IVA sits at the 18.6% percentile with a 14-day RSI of 56.3 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($3.19 to $4.11).

IVA Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are IVA insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies IVA leadership and institutional positioning as: BALANCED INSTITUTIONAL POSITIONING.

Direct Sub-Reports: IVA RQD Cockpit IVA 12M Forecast IVA Earnings & Move IVA Dividends & DRIP IVA Insiders & 13F IVA Whale Options IVA Profit Sankey IVA News & Why
ROARABLE RATING BRIEF • RQD 49/100 (D) ✓ STAGE-C NUMBER FIREWALL VERIFIED

IVA — Inventiva S.A. American Depository Shares: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T14:14:37Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, IVA carries an RQD Score of 49 out of 100, a letter grade of D, and the verdict label "Roarable Sell — Underperform / Distribution Warning." Across the five pillars, the Fundamental Cash Engine scores 12 out of 20 (ROIC 0%; FCF yield 0%), indicating that the source data shows no return on invested capital and no free cash flow yield. Whale 13F Flow scores 7 out of 20 for institutional accumulation and options positioning. Insider Conviction scores 9 out of 20 based on SEC Form 4 and Congressional PTR cluster flow. Macro Regime Fit scores 8 out of 20, with a beta of 1.0 and sector sensitivity. Forensic Balance Sheet scores 13 out of 20, supported by an Altman Z of 2.5, a Piotroski F of 6/9, and a Debt/Equity of 0.5.

For a prospective investor evaluating the stock today, the rating points to weak cash-generation evidence and a negative verdict, with the balance-sheet pillar being the relatively stronger component. Upside drivers cannot be assessed from the cash-engine pillar given its 0% readings. Valuation tradeoffs cannot be fully characterized because P/E, forward P/E, EV/EBITDA, and EPS are not available in source data. The verdict label itself signals distribution risk per the RQD framework.

Open Questions

  • What are the reported revenue, operating income, net income, and free cash flow figures across recent periods, given that the financials section is empty?
  • What is the company's valuation on earnings and cash-flow metrics, given that P/E, EV/EBITDA, and EPS are not available in source data?
  • What are the company's products, customers, and revenue drivers, since the profile does not describe them?
  • Which institutional holders, insiders, or Congressional traders have transacted in IVA, given that the holders section is empty?
  • What recent catalysts or news events could affect the stock, given that no news or catalysts are provided?

IVA Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Inventiva S.A. American Depository Shares (IVA) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to IVA Debate Forum (3) ↓
🟡 MARKET WIRE Yahoo Finance • 35d ago
Inventiva Q2 Earnings Call Highlights

Inventiva (NASDAQ:IVA) said it remains on track to report top-line results from its Phase III NATiV3 trial of lanifibranor in metabolic dysfunction-associated steatohepatitis, or MASH, in the fourth quarter of 2026, afte

Read Full Source ↗
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

IVA Bull vs. Bear Conversation Board — What's Your Call at $3.65?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON IVA 🐻 50% BEARISH CONVICTION
1. Pick Your Side on IVA:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $4.03 (+8.0%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is IVA (D • RQD 49/100) a Buy at $3.73?

Welcome to the IVA (Inventiva S.A. American Depository Shares) Roar Pit. Current RQD Composite is 49/100 (Roarable Sell — Underperform / Distribution Warning) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

SK SkepticalCFA Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $3.10 (-16.9%)
Spot @ $3.73

Pump the brakes on IVA — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on IVA, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Inventiva S.A. American Depository Shares expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

AL AlphaFlow_Cap Verified K Arena Trader 🐂 BULLISH 🎯 Target: $4.48 (+20.1%)
Spot @ $3.73

IVA cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on IVA, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $3.73 (52-wk range $2.82 - $7.29), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%